Theravance Biopharma (NASDAQ:TBPH) Given New $15.00 Price Target at TD Cowen

Theravance Biopharma (NASDAQ:TBPH) had its price objective boosted by analysts at TD Cowen from $13.00 to $15.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. TD Cowen’s target price would indicate a potential upside of 2.10% from the stock’s current price.

A number of other brokerages have also recently commented on TBPH. BTIG Research reiterated a “buy” rating and set a $21.00 target price on shares of Theravance Biopharma in a report on Friday. Oppenheimer cut Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, B. Riley Financial reissued a “neutral” rating and issued a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.33.

Theravance Biopharma Trading Up 2.5%

Shares of TBPH stock traded up $0.36 during trading hours on Monday, hitting $14.69. The company’s stock had a trading volume of 235,581 shares, compared to its average volume of 618,360. The business has a fifty day moving average of $18.00 and a 200-day moving average of $16.89. Theravance Biopharma has a twelve month low of $7.90 and a twelve month high of $21.03. The stock has a market cap of $744.39 million, a price-to-earnings ratio of 7.24 and a beta of 0.17.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in shares of Theravance Biopharma in the 1st quarter valued at $101,000. Jane Street Group LLC raised its position in shares of Theravance Biopharma by 169.2% in the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after buying an additional 88,540 shares during the period. Geode Capital Management LLC raised its position in shares of Theravance Biopharma by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock worth $9,863,000 after buying an additional 3,416 shares during the period. Creative Planning acquired a new position in Theravance Biopharma in the second quarter valued at $139,000. Finally, American Century Companies Inc. boosted its holdings in Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 5,794 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.